

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6551085

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
PIONEER HI-BRED INTERNATIONAL, INC.	12/18/2020
RECEIVING PARTY DATA	
Name:	CARIBOU BIOSCIENCES, INC.
Street Address:	2929 7TH STREET, SUITE 105
City:	BERKELEY
State/Country:	CALIFORNIA
Postal Code:	94710
PROPERTY NUMBERS Total: 10	
Property Type	Number
Application Number:	15008054
Application Number:	15238464
Application Number:	15408920
Application Number:	15493744
Application Number:	15679555
Application Number:	15845524
Application Number:	16670832
Application Number:	16941130
Application Number:	62108931
Application Number:	62251548
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	5109826030
Email:	bmcclung@cariboubio.com
Correspondent Name:	CARIBOU BIOSCIENCES, INC.
Address Line 1:	2929 7TH STREET, SUITE 105
Address Line 4:	BERKELEY, CALIFORNIA 94710
ATTORNEY DOCKET NUMBER:	DUP010

NAME OF SUBMITTER:	KATHARINA F.S. STENGEL
SIGNATURE:	/Katharina F.S. Stengel/
DATE SIGNED:	02/12/2021
Total Attachments: 4 source=chRDNA assignment#page1.tif source=chRDNA assignment#page2.tif source=chRDNA assignment#page3.tif source=chRDNA assignment#page4.tif	

ASSIGNMENT

WHEREAS, Pioneer Hi-Bred International, Inc. ("Assignor"), having a place of business at 7100 NW 62nd Avenue, PO Box 1014, Johnston, IA 50131 USA, owns the entire right, title, and interest in and to the inventions directed to CRISPR hybrid RNA-DNAs (chRDNA) ("Inventions") disclosed in the patents and patent applications set forth on Exhibit A attached hereto (collectively, the "Patents/Applications"); and

WHEREAS, Caribou Biosciences, Inc. ("Assignee"), having a place of business at 2929 7th Street, Suite 105, Berkeley, CA 94710 USA, is desirous of acquiring the entire right, title, and interest in and to the Patents/Applications, and the Inventions disclosed therein;

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by the Assignor to have been received from the Assignee:

1. The Assignor does hereby sell, assign, transfer, and convey unto the Assignee the entire right, title, and interest (a) in and to the Inventions; (b) in and to the Patents/Applications, including the right to claim priority to and from each and every Patent/Application; (c) in and to each and every patent application that is a divisional, substitution, continuation, or continuation-in-part of any of the Patents/Applications; (d) in and to the Patents/Applications and each and every patent issuing or reissuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal, or extension of any kind of any of the foregoing; and (f) in and to all claims for past, present, and future infringement of the Patents/Applications, including all rights to sue for and to receive and recover as Assignee's property and for Assignee's own use, all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of any of the Patents/Applications.

2. The Assignor hereby covenants and agrees to cooperate with the Assignee to enable the Assignee to enjoy to the fullest extent the right, title, and interest of the Inventions and Patents/Applications. Such cooperation by the Assignor shall include prompt production of pertinent facts and documents; giving of testimony; execution of petitions, oaths, specifications, declarations, or other papers; and such other assistance to the extent deemed necessary or desirable by the Assignee (a) for perfecting in the Assignee the right, title, and interest herein conveyed, including executing any separate assignments necessary for individual countries or regions; (b) for prosecuting any patent applications covering the Inventions; (c) for filing and prosecuting any divisionals, substitutions, continuations, or continuations-in-part claiming priority to the Patents/Applications, or additional patent applications covering the Inventions; (d) for filing and prosecuting any applications for reissuance of any of the Patents; (e) for administrative proceedings involving any of the Patents/Applications and Inventions, including, without limitation, interferences, oppositions, reexaminations, and other post-grant proceedings, etc.; and (f) for legal proceedings involving any of the Patents/Applications and Inventions, including, without limitation, infringement actions, invalidity challenges, public use proceedings, etc.

3. The terms and covenants of this Assignment shall inure to the benefit of the Assignee, its successors, assignees, and other legal representatives and shall be binding upon the Assignor, its successors, assignees, and other legal representatives.

4. The Assignor hereby warrants, represents, and covenants that the Assignor has not entered and will not enter into any assignment, contract, or understanding in conflict with this Assignment.

5. The Assignor hereby requests that any patents issuing from Applications set forth on Exhibit A be issued in the name of the Assignee, or its successors or assignees, for the sole use of the Assignee, its successors, legal representatives, and assignees.

6. This Assignment will be interpreted and construed in accordance with the laws of the State of Delaware, United States of America, without regard to conflict of law principles. If any provision of this Assignment is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This Assignment may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same Assignment.

IN WITNESS WHEREOF, the authorized representatives of the Assignor and Assignee have executed this Assignment effective as of December 18, 2020.


Assignor: Pioneer Hi-Bred International, Inc.

Signature: 

Name: Mathias L. Müller

Title: Director, Technology Acquisition & Licensing

same **Assignee: Caribou Biosciences, Inc.**

Signature: 

Name: Rachel E. Haurwitz, Ph.D.

Title: President & CEO

Exhibit A

Country	Application number Patent number	Filing date Grant date	Status
US	15/008,054 9,650,617	01/27/2016 05/16/2017	Granted
US	15/238,464 9,580,701	08/16/2016 02/28/2017	Granted
US	15/408,920 9,688,972	01/18/2017 06/27/2017	Granted
US	15/493,744 9,771,601	04/21/2017 09/26/2017	Granted
US	15/679,555 9,868,962	08/17/2017 01/16/2018	Granted
US	15/845,524 10,519,468	12/18/2017 12/31/2019	Granted
US	16/670,832	10/31/2019	Pending
US	16/941,130	07/28/2020	Pending
US	62/108,931	01/28/2015	Expired
US	62/251,548	11/05/2015	Expired
WO	PCT/US2016/015145	01/27/2016	National phase
AU	2016211517	01/27/2016	Pending
BR	112017016080-3	01/27/2016	Pending
BR	122019001480-9	01/27/2016	Pending
CA	2,975,166 2,975,166	01/27/2016 01/14/2020	Granted
CA	3,060,508	01/27/2016	Pending
CN	201680007759.X	01/27/2016	Abandoned
CN	202010419105.6	01/27/2016	Pending
EP	16704978.2	01/27/2016	Pending
HK(EP)	18105414.7	01/27/2016	Pending
IL	253608 253608	01/27/2016 02/28/2019	Granted
IL	262042 262042	01/27/2016 07/01/2020	Granted
IL	273147	01/27/2016	Pending
IN	201717030003	01/27/2016	Pending
JP	2017-539643	01/27/2016	Pending
JP	2019-099850	01/27/2016	Pending
KR	2017-7023452	01/27/2016	Abandoned
KR	2019-7001414	01/27/2016	Pending
KR	2019-7028425	01/27/2016	Pending
MX	MX/a/2017/009506	01/27/2016	Pending
NZ	733702	01/27/2016	Pending

RU	2017130143 2713328	01/27/2016 02/04/2020	Granted
SG	11201705788T 11201705788T	01/27/2016 06/20/2018	Granted
SG	10201804715W 10201804715W	01/27/2016 07/17/2019	Granted
SG	10201906513W	01/27/2016	Pending
ZA	2017/05174 2017/05174	01/27/2016 12/19/2018	Granted
ZA	2018/03945 2018/03945	01/27/2016 09/25/2019	Granted